Can Rinvoq (upadacitinib) raise cholesterol?
Yes. Rinvoq can increase blood cholesterol levels, including both LDL and HDL, in some patients. This is a known potential effect of Janus kinase (JAK) inhibitors, including upadacitinib. The prescribing information includes cholesterol increases among the monitored lab changes for people starting or staying on Rinvoq [1].
What cholesterol changes do people typically see on Rinvoq?
Patients may have rises in lipid levels on treatment. Clinicians often monitor these values after starting therapy and manage cardiovascular risk factors as needed. If your cholesterol is already high or you have heart disease risk factors, your clinician may check lipids more closely and adjust preventive strategies such as diet, lifestyle, and cholesterol-lowering medicines [1].
How soon after starting Rinvoq does cholesterol rise?
Cholesterol changes are typically identified through routine lab monitoring after initiation rather than at a single moment. Your prescriber will decide when to recheck fasting (or non-fasting) lipid levels based on your baseline results and overall risk profile [1].
What should you do if your cholesterol goes up while on Rinvoq?
Common next steps are to confirm the result with repeat labs and address cardiovascular risk. That can include:
- Reviewing diet and other lifestyle factors that affect cholesterol
- Treating high cholesterol with standard therapies when appropriate (for example, statins), based on your overall cardiovascular risk
- Continuing Rinvoq if the benefit outweighs the risk, unless your clinician recommends a change
Your prescribing clinician is the one to guide whether Rinvoq should be continued or modified based on the size of the lipid increase and your health history [1].
Does Rinvoq affect triglycerides too?
Rinvoq can affect lipid measures broadly, so triglycerides may also change along with LDL and HDL. Lipid panels are the way clinicians track the pattern and decide what to treat [1].
Who should be extra cautious?
People with known hyperlipidemia, diabetes, heart disease, prior stroke, or other cardiovascular risk factors may need closer lipid monitoring after starting Rinvoq. If you have a history of very high cholesterol or already require lipid-lowering therapy, tell your prescriber so the monitoring plan can be adjusted [1].
Sources
- Rinvoq (upadacitinib) Prescribing Information – Abbott/EMA label (cholesterol and lipid monitoring)